- Home
- MFIN vs KOD Comparison
MFIN vs KOD Comparison
Compare MFIN & KOD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MFIN
- KOD
- Stock Information
- Founded
- MFIN 1995
- KOD 2009
- Country
- MFIN United States
- KOD United States
- Employees
- MFIN N/A
- KOD N/A
- Industry
- MFIN Finance: Consumer Services
- KOD Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MFIN Finance
- KOD Health Care
- Exchange
- MFIN Nasdaq
- KOD Nasdaq
- Market Cap
- MFIN 223.8M
- KOD 198.4M
- IPO Year
- MFIN 1996
- KOD 2018
- Fundamental
- Price
- MFIN $10.13
- KOD $10.57
- Analyst Decision
- MFIN Strong Buy
- KOD Hold
- Analyst Count
- MFIN 1
- KOD 4
- Target Price
- MFIN $12.00
- KOD $11.25
- AVG Volume (30 Days)
- MFIN 77.7K
- KOD 715.4K
- Earning Date
- MFIN 07-30-2025
- KOD 08-13-2025
- Dividend Yield
- MFIN 4.74%
- KOD N/A
- EPS Growth
- MFIN N/A
- KOD N/A
- EPS
- MFIN 1.75
- KOD N/A
- Revenue
- MFIN $332,256,000.00
- KOD N/A
- Revenue This Year
- MFIN N/A
- KOD N/A
- Revenue Next Year
- MFIN $5.67
- KOD N/A
- P/E Ratio
- MFIN $5.78
- KOD N/A
- Revenue Growth
- MFIN 16.48
- KOD N/A
- 52 Week Low
- MFIN $7.40
- KOD $1.92
- 52 Week High
- MFIN $10.98
- KOD $11.60
- Technical
- Relative Strength Index (RSI)
- MFIN 52.18
- KOD 77.63
- Support Level
- MFIN $9.86
- KOD $7.69
- Resistance Level
- MFIN $10.51
- KOD $8.45
- Average True Range (ATR)
- MFIN 0.40
- KOD 0.83
- MACD
- MFIN -0.02
- KOD 0.17
- Stochastic Oscillator
- MFIN 24.11
- KOD 85.66
About MFIN Medallion Financial Corp.
Medallion Financial Corp is a finance company that originates and services loans in various industries. The five operating segments are, (1) recreation, (2) home improvement, (3) commercial, (4) taxi medallion, and (5) strategic partnership loans. The company generates maximum revenue from the Recreation segment.
About KOD Kodiak Sciences Inc
Kodiak Sciences Inc is a biopharmaceutical company specializing in novel therapeutics to treat high-prevalence retinal diseases. The product candidate of the company is BLA, which is a novel antibody biopolymer conjugate, in treatment-naive subjects with neovascular wet AMD. The pipeline products of the company include Tarcocimab tedromer, KSI-501, and KSI-101.